Category: ASCO
-
STAT+: On ASCO Day 4, J&J bets on Rybrevant and airs ‘innovation ecosystem’ concerns
STAT+: On ASCO Day 4, J&J bets on Rybrevant and airs ‘innovation ecosystem’ concerns This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter here. ASCO ends tomorrow, but alas, dear readers,…
-
STAT+: At ASCO Day 3, AstraZeneca dominates, Takeda reveals experimental drug data, Eli Lilly serves salad
STAT+: At ASCO Day 3, AstraZeneca dominates, Takeda reveals experimental drug data, Eli Lilly serves salad This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter here. We’re going to get to…
-
Study finds exercise can keep colon cancer from recurring
Study finds exercise can keep colon cancer from recurring CHICAGO — An exercise program can reduce the risk that colorectal cancer will return after surgery and chemotherapy, according to a new study. The benefit from the study’s exercise program was about as large as what researchers might expect from a new drug, experts said, and…
-
STAT+: AstraZeneca’s CEO balances cancer-fighting opportunities with political uncertainty
STAT+: AstraZeneca’s CEO balances cancer-fighting opportunities with political uncertainty CHICAGO — Each year, 40,000 cancer researchers, doctors, and industry executives gather here for the biggest meeting in oncology. And for seven years, it has been almost assumed that the medicines generating the most buzz will come from AstraZeneca. Perhaps that’s why, in a wood-paneled conference…
-
STAT+: Combination treatment reduces risk of tumor progression in aggressive form of breast cancer, study shows
STAT+: Combination treatment reduces risk of tumor progression in aggressive form of breast cancer, study shows CHICAGO — A treatment that combines two different types of cancer-fighting medicines — Gilead Sciences’ Trodelvy with Merck’s Keytruda — reduced the risk of tumor progression by more than one-third in women with an aggressive form of breast cancer. …
-
STAT+: As Trump proposes NIH cuts, a top Merck executive sees fragility in a ‘super-highway for biomedicine’
STAT+: As Trump proposes NIH cuts, a top Merck executive sees fragility in a ‘super-highway for biomedicine’ CHICAGO — Amid ongoing uncertainty around funding for the National Institutes of Health, and what it could mean for U.S. innovation, a top Merck executive stressed that the agency is “an incredible super-highway for biomedicine,” and that it’s “a…
-
STAT+: ASCO day 2: A tragic paradox, Gilead updates, and lots of Pfizer news
STAT+: ASCO day 2: A tragic paradox, Gilead updates, and lots of Pfizer news This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter here. ASCO is usually sweltering, but it’s…
-
At ASCO 2025, attendees see reason for hope, despite worries
At ASCO 2025, attendees see reason for hope, despite worries For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter here. The annual meeting of the American Society of Clinical Oncology is now in session. As always, STAT has your appetite for cancer news covered. Reporters Matt Herper, Adam…
-
STAT+: Merus drug, with immunotherapy, shows preliminary survival boost for patients with head and neck cancer
STAT+: Merus drug, with immunotherapy, shows preliminary survival boost for patients with head and neck cancer Merus said Thursday that a combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda has kept 79% of patients with newly diagnosed metastatic head and cancer alive for at least one year, according to a new analysis…
-
STAT+: ASCO and Google create ‘walled garden’ AI tool for doctors to query group’s guidelines
STAT+: ASCO and Google create ‘walled garden’ AI tool for doctors to query group’s guidelines The American Society of Clinical Oncology, the largest professional organization in cancer care, announced Wednesday that it had partnered with Google Cloud to develop an AI-based tool to help physicians rapidly question the organization’s guidelines on best practices in diagnosing…